G. Basaran Et Al. , "Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.," Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , vol.38, ELECTR NETWORK, 2020
Basaran, G. Et Al. 2020. Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , (ELECTR NETWORK).
Basaran, G., Demirci, U., Yildiz, F., Cicin, I., Aktas, B. Y., Ozturk, B., ... Goksu, S. S.(2020). Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey. . Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK
Basaran, Gül Et Al. "Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.," Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2020
Basaran, Gül Et Al. "Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , ELECTR NETWORK, 2020
Basaran, G. Et Al. (2020) . "Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.." Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) , ELECTR NETWORK.
@conferencepaper{conferencepaper, author={Gül BAŞARAN Et Al. }, title={Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.}, congress name={Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)}, city={}, country={ELECTR NETWORK}, year={2020}}